(Q37771029)

22 August 2017

1 reference

title

Predicting and preventing acute drug-induced liver injury: what's new in 2010? (English)

1 reference

22 August 2017

Gordon Liss

1

1 reference

22 August 2017

Sushil Rattan

series ordinal

2

1 reference

22 August 2017

James H Lewis

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

9

1 reference

22 August 2017

1047-1061

1 reference

Review article: drug-induced liver injury in clinical practice

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Drug-induced liver injury: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Hepatotoxicity of drugs and chemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Diagnosis, management and prevention of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Drug-induced liver injury: what was new in 2008?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Outcome and prognostic markers in severe drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Management of hepatic complications in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Pharmacogenomics in drug induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Use of transcriptomics in understanding mechanisms of drug-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

In vitro evaluation of potential hepatotoxicity induced by drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Genetic association studies in drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Drug-induced liver injury: insights from genetic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

The current state of serum biomarkers of hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Translational toxicology and the work of the predictive safety testing consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Monitoring statin safety in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Compliance to recommended liver function monitoring in patients on statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Liver enzyme monitoring in patients treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

A difficult balance--pain management, drug safety, and the FDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Acute liver failure due to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Causality assessment of drug-induced hepatotoxicity: promises and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Review article: The use of potentially hepatotoxic drugs in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Therapeutic dose of acetaminophen may induce fulminant hepatitis in the presence of risk factors: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Association of acetaminophen hepatotoxicity with fasting and ethanol use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Role of c-Jun N-terminal kinase (JNK) in regulating tumor necrosis factor-alpha (TNF-alpha) mediated increase of acetaminophen (APAP) and chlorpromazine (CPZ) toxicity in murine hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Adverse reactions associated with acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

A role for the pregnane X receptor in flucloxacillin-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Pharmacogenetics of antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Antiretroviral therapy hepatotoxicity: Prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Drug-induced liver injury in humans: the case of ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Drug-induced liver injury associated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Herbal and dietary supplement hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Successful translation of pharmacogenetics into the clinic: the abacavir example

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Drug-induced liver injury: is it somehow foreseeable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients--a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

A study of HIV provider attitudes toward HLA-B 5701 testing in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Therapy of hepatitis C in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Management of individuals requiring antiretroviral therapy and TB treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Hepatotoxicity and antituberculosis therapy: time to revise UK guidance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Toxicity of first-line drugs for treatment of tuberculosis in children: review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

The state of dietary supplement adverse event reporting in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Physician knowledge of herbal toxicities and adverse herb-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Hepatotoxicity due to hydroxycut: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Hepatotoxicity from green tea: a review of the literature and two unpublished cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Suspected black cohosh hepatotoxicity--challenges and pitfalls of causality assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Drug-induced liver injury in clinical trials: as rare as hens' teeth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Metabolomics study with gas chromatography-mass spectrometry for predicting valproic acid-induced hepatotoxicity and discovery of novel biomarkers in rat urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Ornithine carbamyltransferase is a sensitive marker for alcohol-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

Genetic predisposition to drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.503706

10.1517/17425255.2010.503706

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference